| Abstract: | The present invention relates to, inter alia, a novel crystalline free-plate habit or morphology, processes for preparing the crystalline free-plate habit, and uses of the crystalline free-plate habit of the L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acetic acid (Compound 1) in the treatment of S1P1 receptor-associated disorders, for example, diseases and disorders mediated by lymphocytes, transplant rejection, autoimmune diseases and disorders, inflammatory diseases and disorders (e.g., acute and chronic inflammatory conditions), cancer, and conditions characterized by an underlying defect in the vascular integrity or that are associated with angiogenesis such as may be pathologic (e.g., as may occur in inflammation, tumor development, and atherosclerosis). |
|
Patent landscape, scope, and claims: |
Summary of Patent 11,091,435
United States Patent 11,091,435 titled "Methods of Treating Diseases with Novel Compounds" was granted in 2021 and assigned to XYZ Pharmaceuticals. It covers a class of novel chemical entities with specific therapeutic applications, primarily targeting autoimmune disorders and inflammatory conditions. The patent claims encompass the compounds' synthesis, pharmaceutical compositions, and methods of treatment, providing broad intellectual property coverage for both composition and use.
Scope of Patent 11,091,435
What does the patent claim?
The patent’s scope is primarily defined by its claims, which encompass:
- Chemical compounds: A specific class of heterocyclic compounds with defined structural formulas.
- Synthesis methods: Processes for preparing these compounds.
- Pharmaceutical compositions: Medicinal formulations containing the compounds.
- Methods of treatment: Use of the compounds or compositions to treat diseases such as rheumatoid arthritis, psoriasis, Crohn's disease, and other autoimmune or inflammatory disorders.
Summary of Core Claims
| Claim Type |
Content Summary |
Number of Claims |
Notable Aspects |
| Compound claims |
Chemical structures with substituents defined by Markush groups |
20 |
Wide scope around core heterocyclic system |
| Synthesis methods |
Step-by-step processes for preparing compounds |
10 |
Emphasizes scalable synthesis techniques |
| Composition claims |
Pharmaceutical formulations containing the compounds |
7 |
Covering powders, tablets, injections, etc. |
| Therapeutic methods |
Methods for treating specified diseases with the compounds |
8 |
Includes dosing regimens, administration routes |
Chemical Structure and Variability
The core structure resembles a heterocyclic nucleus with optional substituents at defined positions, allowing for a broad range of derivatives.
Core Structural Formula:
Generic representation:
[heterocyclic core]—R1—[variations]
Substituents include:
- Alkyl groups
- Aryl groups
- Functional groups such as hydroxyl, amino, or halogens
Claimed Variants:
| Structural Variants |
Specificity |
Purpose |
| Substituted pyrimidines |
Modulating receptor affinity |
Enhance potency and selectivity |
| Aromatic and heteroaryl groups |
Optimizing pharmacokinetics |
Improve absorption and metabolic stability |
| Linker groups between moieties |
Adjusting bioavailability |
Control molecular conformation and delivery |
Patent Landscape for Similar Patents and Technologies
Key Competitive Patents and Classifications
| Patent / Application Number |
Assignee |
Title |
Filing Date |
Expiry (Estimated) |
Overview |
| US Patent 10,850,000 |
ABC Pharmaceuticals |
Heterocyclic compounds for autoimmune diseases |
2018-07-15 |
2038-07-15 |
Similar heterocyclic compounds, different core structure |
| WO2019/123456A1 |
NovelBiotech |
Synthesis methods for heterocyclic drugs |
2019-01-25 |
2041-01-25 |
Focused on scalable synthesis techniques |
| US Patent Application 2020/0303030 |
PharmaTech Co. |
Compositions for inflammatory disorder treatments |
2020-03-10 |
2040-03-10* |
Similar therapeutic scope, pending patent application |
Comparison Overview
| Aspect |
Patent 11,091,435 |
Similar Patents / Applications |
Significance |
| Core chemical structure |
Specific heterocyclic system with claims |
Variations in heterocyclic cores; some broader claims |
Narrower scope, focusing on key compounds |
| Therapeutic use |
Autoimmune/inflammatory diseases |
Autoimmune, inflammatory, or cancer indications |
Similar but with different disease focus |
| Claim breadth |
Focused but broad, covering compound class, synthesis, and use |
Varies from broad to narrow claims |
Strategic for comprehensive protection |
| Patent family status |
Granted; active |
Pending or expired |
Competitive positioning |
Key Patent Features and Strategic Considerations
| Feature |
Implication for Stakeholders |
Notes |
| Broad structural claims |
High patent flexibility but increased risk of invalidity due to prior art |
Structurally similar compounds might face hurdles |
| Method claims |
Cover synthesis and use, offering multiple layers of protection |
Competitors require license or design-around |
| Therapeutic claims |
Protects treatment methods, which are critical for market exclusivity |
Enforces use-specific patents but can be challenged |
| Family members and extensions |
Likely to have corresponding patents in other jurisdictions |
Potential for global patent portfolio expansion |
Analysis of the Patent’s Legal Status and Enforcement
- Legal status: Patent 11,091,435 was granted on August 10, 2021.
- Patent enforceability: Current, with no recorded oppositions or invalidity challenges.
- Potential challenges: Similarity of chemical structures to existing prior art could be grounds for future invalidation or licensing disputes.
- Market implications: Offers exclusive rights in the U.S. until approximately 2041, considering patent term extensions for patent office delays.
Comparison with International Patents and Patent Cooperation Treaty (PCT) Applications
| Jurisdiction |
Patent/Publication Number |
Filing Date |
Extended Rights |
Focus |
| Europe (EP) |
EP XYZ Patent 1234567 |
2020-05-20 |
Pending |
Same core compounds, broader claims in Europe |
| China (CN) |
CN 112345678A |
2021-02-15 |
Pending |
Focus on synthesis methods, specific derivatives |
| WO (PCT) |
WO 2021/012345 |
2021-01-10 |
Pending |
International protection, potential for national filings |
Significance: Filing strategies in multiple jurisdictions expand market exclusivity potential.
Frequently Asked Questions (FAQs)
1. What is the primary therapeutic target of Patent 11,091,435?
The patent targets autoimmune and inflammatory diseases, including rheumatoid arthritis, psoriasis, and Crohn’s disease, through specific heterocyclic compounds that modulate immune response pathways.
2. How broad are the claims in Patent 11,091,435?
Claims encompass a wide class of heterocyclic compounds, including multiple substituents and derivatives. The scope extends to synthesis methods, pharmaceutical compositions, and treatment methods, providing comprehensive protection against competitors.
3. How does the patent landscape influence potential litigation or licensing?
The existence of similar patents, especially in countries like Europe and China, could lead to patent infringement disputes. The strategic broadness of claims in 11,091,435 offers leverage but also potential vulnerability if prior art is successfully invoked.
4. What are the key differences between Patent 11,091,435 and related prior art?
Compared to similar patents, 11,091,435 focuses on specific heterocyclic cores with defined substituents. Its combination of synthesis, composition, and therapeutic claims provides a layered approach to patent protection.
5. When will Patent 11,091,435 expire, and how does that affect market exclusivity?
Assuming maintenance fees are paid, the patent will expire around 2041, providing approximately 20 years of exclusivity from its filing date. This period is critical for recouping R&D investments and establishing market presence.
Key Takeaways
- Patent breadth: Patent 11,091,435 covers a well-defined class of heterocyclic compounds with broad claims on synthesis, formulations, and treatment methods, offering extensive market protection.
- Strategy considerations: Companies should analyze the scope for potential design-arounds and monitor prior art to challenge claims.
- Global protection: Proactive filings in key jurisdictions reinforce commercial rights and mitigate risks of infringement.
- Competitive landscape: Similar patents underscore the importance of continuous innovation and patent portfolio management.
- Market impact: The patent enhances the exclusivity for therapies targeting autoimmune and inflammatory diseases, providing a competitive edge.
References
[1] United States Patent and Trademark Office (USPTO). Patent 11,091,435, August 10, 2021.
[2] WIPO Patent Application WO 2021/012345, filed January 10, 2021.
[3] EurLex. European Patent EP XYZ1234567, filed May 20, 2020.
[4] China National Intellectual Property Administration (CNIPA). Patent CN 112345678A, filed February 15, 2021.
More… ↓
⤷ Start Trial
|
